International Biotechnology (LON:IBT) Share Price Crosses Above 200 Day Moving Average – What’s Next?

International Biotechnology (LON:IBT) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 689.46 ($8.54) and traded as high as GBX 734 ($9.10). International Biotechnology shares last traded at GBX 726 ($9.00), with a volume of 74,465 shares trading hands.

International Biotechnology Price Performance

The company has a quick ratio of 0.32, a current ratio of 0.46 and a debt-to-equity ratio of 9.66. The business’s 50-day simple moving average is GBX 698.46 and its 200 day simple moving average is GBX 689.46. The firm has a market capitalization of £268.33 million, a P/E ratio of 1,512.50 and a beta of 0.21.

International Biotechnology (LON:IBT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported GBX (9.16) (($0.11)) EPS for the quarter. International Biotechnology had a net margin of 75.33% and a return on equity of 6.25%. Sell-side analysts forecast that International Biotechnology will post 0.9435943 earnings per share for the current year.

International Biotechnology Increases Dividend

The company also recently announced a dividend, which was paid on Friday, January 24th. Stockholders of record on Thursday, December 19th were issued a GBX 15.56 ($0.19) dividend. This is a boost from International Biotechnology’s previous dividend of $14.50. The ex-dividend date was Thursday, December 19th. This represents a dividend yield of 2.21%. International Biotechnology’s dividend payout ratio (DPR) is currently 6,041.67%.

Insider Transactions at International Biotechnology

In related news, insider Katherine Cornish-Bowden purchased 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average price of GBX 713 ($8.84) per share, for a total transaction of £10,695 ($13,254.43). Company insiders own 4.18% of the company’s stock.

About International Biotechnology

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.